Last reviewed · How we verify
Relmacabtagene Autoleucel Injection
At a glance
| Generic name | Relmacabtagene Autoleucel Injection |
|---|---|
| Also known as | CARTEYVA, JWCAR029 |
| Sponsor | Changhai Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies (PHASE2)
- Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma (PHASE2)
- Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma (PHASE4)
- CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma (PHASE1)
- A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma (PHASE4)
- Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (PHASE1)
- Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Relmacabtagene Autoleucel Injection CI brief — competitive landscape report
- Relmacabtagene Autoleucel Injection updates RSS · CI watch RSS
- Changhai Hospital portfolio CI